-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Avibactam + Aztreonam) in Gram-Negative Bacterial Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Avibactam + Aztreonam) in Gram-Negative Bacterial Infections Drug Details: PF-06947387 (aztreonam in combination with avibactam)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Oravance in Gram-Negative Bacterial Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oravance in Gram-Negative Bacterial Infections Drug Details: ORAvance is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Levonadifloxacin in Gram-Negative Bacterial Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Levonadifloxacin in Gram-Negative Bacterial Infections Drug Details:Levonadifloxacin (Emrok) is a broad spectrum synthetic benzoquinolizine fluoroquinolone antibacterial...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nacubactam in Gram-Negative Bacterial Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nacubactam in Gram-Negative Bacterial Infections Drug Details: Nacubactam (RG6080, RO7079901) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Calpurbatug in Gram-Positive Bacterial Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Calpurbatug in Gram-Positive Bacterial InfectionsDrug Details:calpurbatug is under development for the treatment of rhinosinusitis, prosthetic joint infection,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Calpurbatug in Gram-Negative Bacterial Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Calpurbatug in Gram-Negative Bacterial InfectionsDrug Details:calpurbatug is under development for the treatment of rhinosinusitis, prosthetic joint infection,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ceftriaxone in Gram-Positive Bacterial Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ceftriaxone in Gram-Positive Bacterial Infections Drug Details: Ceftriaxone is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ceftriaxone in Gram-Negative Bacterial Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ceftriaxone in Gram-Negative Bacterial Infections Drug Details: Ceftriaxone is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MRX-8 in Gram-Negative Bacterial Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MRX-8 in Gram-Negative Bacterial InfectionsDrug Details:MRX-8 is under development for the treatment of multi-drug resistant gram...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-3402 in Gram-Negative Bacterial Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MK-3402 in Gram-Negative Bacterial Infections Drug Details: MK-3402 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.